

1 **Validation of Saliva and Self-Administered Nasal Swabs for COVID-19 Testing**

2 Alvin Kuo Jing Teo<sup>1</sup>; Yukti Choudhury<sup>2</sup>; Iain Beehuat Tan<sup>3,4,5</sup>; Chae Yin Cher<sup>2</sup>; Shi Hao Chew<sup>6</sup>;

3 Zi Yi Wan<sup>2</sup>; Lionel Tim Ee Cheng<sup>7</sup>; Lynette Lin Ean Oon<sup>8</sup>; Min Han Tan<sup>2</sup>; Kian Sing Chan<sup>7</sup>; Li

4 Yang Hsu<sup>1,9\*</sup>

5

6 <sup>1</sup>Saw Swee Hock School of Public Health, National University of Singapore, National

7 University Health System, Singapore

8 <sup>2</sup>Lucence Diagnostics, Singapore

9 <sup>3</sup>Department of Medical Oncology, National Cancer Centre, Singapore

10 <sup>4</sup>Duke-NUS Graduate Medical School, National University of Singapore

11 <sup>5</sup>Genome Institute of Singapore

12 <sup>6</sup>Headquarters Army Medical Services, Singapore Armed Forces, Singapore

13 <sup>7</sup>Department of Diagnostic Radiology, Singapore General Hospital

14 <sup>8</sup>Department of Molecular Pathology, Singapore General Hospital

15 <sup>9</sup>Yong Loo Lin School of Medicine, National University of Singapore, National University

16 Health System, Singapore

17

18 \*Corresponding author: Li Yang Hsu

19 Address: Saw Swee Hock School of Public Health, National University of Singapore, #10-01,

20 12 Science Drive 2, 117549 Singapore

21 Email: [mdchly@nus.edu.sg](mailto:mdchly@nus.edu.sg)

22

23

24

1 **Abstract**

2 Background

3 Active cases of COVID-19 has primarily been diagnosed via RT-PCR of  
4 nasopharyngeal (NP) swabs. Saliva and self-administered nasal (SN) swabs can be collected  
5 safely without trained staff.

6 We aimed to test the sensitivity of “naso-oro-pharyngeal” saliva and SN swabs  
7 compared to NP swabs in a large cohort of migrant workers in Singapore.

8 Methods

9 We recruited 200 male adult subjects: 45 with acute respiratory infection, 104  
10 asymptomatic close contacts, and 51 confirmed COVID-19 cases. Each subject underwent  
11 NP swab, SN swab and saliva collection for RT-PCR testing at 1 to 3 timepoints. We  
12 additionally used a direct-from-sample amplicon-based next-generation sequencing (NGS)  
13 workflow to establish phylogeny.

14 Results

15 Of 200 subjects, 91 and 46 completed second and third rounds of testing,  
16 respectively. Of 337 sets of tests, there were 150 (44.5%) positive NP swabs, 127 (37.7%)  
17 positive SN swabs, and 209 (62.0%) positive saliva.

18 Test concordance between different sample sites was good, with a kappa statistic of  
19 0.616 for NP and SN swabs, and 0.537 for NP and saliva. In confirmed symptomatic COVID-  
20 19 subjects, the likelihood of a positive test from any sample fell beyond 14 days of  
21 symptom onset.

22 NGS was conducted on 18 SN and saliva samples, with phylogenetic analyses  
23 demonstrating lineages for all samples tested were Clade O (GISAID nomenclature) and  
24 lineage B.6 (PANGOLIN nomenclature).

1 Conclusion

2           This study supports saliva as a sensitive and less intrusive sample for COVID-19  
3 diagnosis and further delineates the role of oropharyngeal secretions in increasing the  
4 sensitivity of testing. However, SN swabs were inferior as an alternate sample type. Our  
5 study also provides evidence that a straightforward next-generation sequencing workflow  
6 can provide direct-from-sample phylogenetic analysis for public health decision-making.

7

## 1 **Introduction**

2           The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged from  
3 Wuhan, China in November 2019 [1], and has since caused a global pandemic, with over  
4 13.4 million confirmed COVID-19 cases and 581,000 deaths as of 15<sup>th</sup> July 2020 [2].  
5 Singapore has not been spared, with over 46,000 cases and 27 deaths since the first case  
6 was reported on 23<sup>rd</sup> January 2020, the majority of cases being migrant workers living in  
7 crowded dormitories [3].

8           The principal method for diagnosing active cases of coronavirus disease 2019  
9 (COVID-19) has been through the detection of viral genetic material via reverse  
10 transcription-polymerase chain reaction (RT-PCR). In Singapore and several other countries,  
11 nasopharyngeal (NP) swabs are the principal means for collecting specimens for testing [4,5].  
12 However, NP swabs could cause discomfort and require trained healthcare staff to perform.  
13 In situations where mass or community screening is required, the resources required to  
14 organize NP swabbing can be considerable, such as the drive-through screening centres  
15 pioneered by South Korea [6].

16           Saliva and self-administered nasal (SN) swabs are, in many ways, ideal specimens for  
17 COVID-19 screening. Both can be collected safely without the need for trained staff. The  
18 utility of saliva for COVID-19 testing has been tested in multiple territories and countries,  
19 including Hong Kong [7-9], China [10], Italy [11], Australia [12], North America [13,14], and  
20 Japan [15].

21           The majority of current published studies involve relatively small numbers of  
22 subjects with heterogeneous results, and a meta-analysis suggests that saliva is at best  
23 slightly less sensitive or similar to other specimens, including NP swabs [16]. One caveat  
24 relates to how saliva is collected—saliva is a complex bio-mixture which can consist of

1 salivary gland secretion, gingival crevicular fluid, sputum and/or mucosal transudate, in  
2 varying proportions depending on collection method. Some studies tested only secretions  
3 from the mouth [11,12], others explicitly tested “posterior oropharyngeal” or “deep throat”  
4 saliva with secretions from the oropharynx [7-10], while the rest were unspecified [13-16].

5 We aimed to test the sensitivity of “naso-oropharyngeal” saliva and SN swabs  
6 compared to NP swabs in a large cohort of migrant workers in Singapore using RT-PCR  
7 testing. We additionally used a direct-from-sample amplicon-based next-generation  
8 sequencing (NGS) workflow to establish phylogeny for tested samples.

9

## 10 **Methods**

### 11 Study Population

12 Subjects were recruited from two sites – a large 5,400-bed purpose-built dormitory  
13 where migrant workers were housed in large rooms holding between 7 and 20 workers, and  
14 a community care facility (CCF) where migrant workers diagnosed with COVID-19 via prior  
15 RT-PCR testing but not requiring acute hospital care were sent for monitoring and isolation.  
16 All subjects at the CCF are prior confirmed cases, while subjects from the dormitory  
17 comprised of two groups—1) migrant workers presenting with symptoms of acute  
18 respiratory tract infection (ARI); and 2) asymptomatic roommates of newly diagnosed  
19 COVID-19 cases.

20

### 21 Sample Collection

22 Migrant workers from the purpose-built dormitory presenting with ARI were  
23 assessed at the medical post, where the decision for NP swab for diagnosis of COVID-19 was  
24 made by the physician-in-charge. After their routine nasopharyngeal swabs were obtained

1 by a trained healthcare worker, these workers were immediately approached for study  
2 participation, and consent taken where agreeable. Demonstration videos on the  
3 performance of SN swab and naso-oro-pharyngeal saliva collection in the major native  
4 languages of the migrant workers (English *video link: <https://youtu.be/4jGrJUbjBBs>*) were  
5 shown, following which these samples were collected under the supervision of a trained  
6 researcher. For other groups of consenting subjects from community care facility (CCF)  
7 previously diagnosed with COVID-19, the NP swab was performed by a trained researcher  
8 following collection of the SN swab and naso-oro-pharyngeal saliva in the same sitting.

9 We planned for each subject to be tested up to three times at 2–3-day intervals  
10 where possible, in order to compare the sensitivity of different samples across time.  
11 Subjects from the purpose-built dormitory who tested negative across all three samples  
12 during the first round of testing were not retested. Subjects from the CCF were not retested  
13 if all samples from the initial two rounds were negative.

14 NP swabs from subjects with ARI were sent dry in cooler boxes to the Singapore  
15 General Hospital (SGH) molecular laboratory as part of routine clinical testing and processed  
16 within the same day. NP swabs and SN swabs from other subjects were sent in 3 mls of viral  
17 transport medium, while between 1–2 mls of oro-pharyngeal saliva was collected in a  
18 container with 2 mls of viral RNA stabilization fluid (SAFER<sup>TM</sup>-Sample Stabilization Fluid,  
19 Lucence, Singapore) before transfer to Lucence Laboratory with processing occurring within  
20 the same day. Both service laboratories are College of American Pathologists (CAP)  
21 accredited.

22

23 Laboratory Testing

1 RT-PCR at SGH was performed using the cobas®SARS-CoV-2 (Roche Molecular  
2 Systems, Branchburg, NJ) on an automated cobas®6800 system, with results called  
3 according to the manufacturer's specifications.

4 NP and saliva samples sent to Lucence Laboratory underwent RNA extraction (200 µl  
5 of the sample) (GeneAid Biotech Ltd) and were tested with a laboratory-developed RT-PCR  
6 test (CDC-LDT) based on primers published by the Division of Viral Diseases, National Center  
7 for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention,  
8 Atlanta, GA, USA [17], while saliva and SN swabs were additionally tested using the  
9 Fortitude 2.1 kit (MiRXES, Singapore). The analytical limit of detection of the CDC-LDT was  
10 determined to be 25 copies per reaction based on a synthetic SARS-CoV-2 genome (Twist  
11 Bioscience). Saliva was pre-processed with the addition of dithiothreitol (DTT), vortexing  
12 and incubation at room temperature for 15 minutes.

13 SARS-CoV-2 amplicon-based next-generation sequencing (NGS) was done for 18  
14 available samples collected in stabilization fluid from known COVID-19 cases, using 330  
15 primer pairs to generate amplicons (size range 130-178 bp) covering the entire virus  
16 genome (except the first 25 bases and 30 bases upstream of the final polyA tail) to establish  
17 a direct-from-sample workflow. To rule out potential non-specific amplification of other  
18 viruses related in sequence, all amplicons were verified to have limited similarity to  
19 sarbecoviruses, outside of SARS-related coronaviruses (assumed to not be in present  
20 circulation). Ten of 18 samples were paired sets of saliva and SN swab samples from 5  
21 individuals. The remaining 8 comprised 1 SN swab and 7 saliva samples from individual  
22 patients. For samples with complete viral genomes (100% coverage  $\geq$  1X coverage),  
23 phylogenetic analysis was performed to identify lineages based on sequence variants.

24

1 Statistical Methods

2 Intercooled Stata 13.1 (StataCorp, College Station, TX, USA) was used for all  
3 statistical calculations. The kappa statistic was used to measure observer agreement  
4 between sample sites.

5

6 Ethics

7 This study was approved by the Director of Medical Services, Ministry of Health  
8 under Singapore's Infectious Disease Act [18].

9

10 Funding Source

11 This study was funded by a grant from the Changi Airport Group. Fortitude 2.1 kits  
12 were provided by the Diagnostics Development Hub (DxD Hub), A\*ccelerate, Agency for  
13 Science, Technology and Research, Singapore. The study sponsor had no role in the design,  
14 implementation, analysis or write-up of the study.

15

16 **Results**

17 Study recruitment was completed between 2<sup>nd</sup> and 26<sup>th</sup> June 2020. There were 45  
18 subjects with ARI and 104 asymptomatic close contacts recruited from the purpose-built  
19 dormitory, while 51 subjects with confirmed COVID-19 (8 asymptomatic at the time of  
20 diagnosis) were recruited at the CCF.

21 Subject characteristics are displayed in Table 1. Of 200 subjects, 91 and 46  
22 completed second and third rounds of testing, respectively. Because COVID-19-positive  
23 migrant workers were rapidly transferred out of dormitories to CCFs, all but one subject  
24 from the dormitory site did not complete the planned testing. The median time period

1 between the date of diagnosis and the first round of testing in asymptomatic subjects was 0  
2 days (range: 0–6 days) while the median time period between symptom onset and the first  
3 round of testing was 5.5 days (range: 0–28 days).

4 The results of RT-PCR testing are shown in Table 2. Of 337 sets of tests, there were  
5 150 (44.5%) positive NP swabs tested via cobas®SARS-CoV-2 or CDC-LDT, 127 (37.7%)  
6 positive SN swabs tested via CDC-LDT, 119 (35.3%) positive SN swabs tested via Fortitude  
7 2.1, 209 (62.0%) positive saliva tested via CDC-LDT, and 167 (49.6%) positive saliva tested via  
8 Fortitude 2.1. Ct values were generally lower during the earlier period of infection across all  
9 sample types, in particular for symptomatic infections where the onset of illness could be  
10 better estimated (Figure 1).

11 For 63 positive NP swabs with low Ct (<30) values (the lower of results from two  
12 targets), SN swabs were concomitantly positive in 57 (90.5%) and 60 (95.2%) samples, while  
13 saliva was positive in 62 (98.4%) and 61 (96.8%) samples when tested via CDC-LDT and  
14 Fortitude 2.1, respectively. For 87 positive NP swabs with high Ct ( $\geq 30$ ) values, SN swabs  
15 were concomitantly positive in 49 (56.3%) and 48 (55.2%) samples, while saliva was positive  
16 in 77 (88.5%) and 64 (73.6%) samples, respectively. The likelihood of concordant positive  
17 tests in other samples was also high when Ct values were low (<30) in saliva tested via CDC-  
18 LDT—76.9% of NP swabs, 64.0% of SN swabs tested via CDC-LDT, and 62.6% of SN swabs  
19 tested via Fortitude 2.1 were concomitantly positive. However, only 41.9% of SN swabs,  
20 30.7% of SN swabs tested via CDC-LDT, and 27.4% of SN swabs tested via Fortitude 2.1 were  
21 positive in-tandem with saliva samples tested via CDC-LDT when Ct values were high ( $\geq 30$ ).

22 Test concordance between different sample sites was relatively good as evaluated  
23 by Cohen’s kappa coefficient, with the kappa statistic of 0.616 for NP and SN swabs tested  
24 via CDC-LDT (agreement of 81.3%), 0.675 for NP tested via CDC-LDT and SN swabs tested via

1 Fortitude 2.1 (agreement of 84.3%), 0.537 for NP and saliva tested via CDC-LDT (76.2%), and  
2 0.602 for NP tested via CDC-LDT and saliva tested via Fortitude 2.1 (80.1%). Test  
3 concordances were excellent between the two saliva (87.2%) and SN swabs (91.0%) tests,  
4 with a kappa statistic of 0.745 and 0.806, respectively.

5 In the subset of confirmed COVID-19 subjects from the CCF, the likelihood of a  
6 positive test from any sample fell beyond 14 days of symptom onset in symptomatic  
7 subjects, although this was less significant for saliva tested via CDC-LDT (Table 3).

8 Among 18 samples (SN swabs and saliva) from round 1 of sampling tested by NGS as  
9 proof of principle, there was a strong correlation between viral genome coverage (%) by  
10 NGS and Ct values for SARS-CoV-2, with 10 samples showing 100% coverage (7 unique  
11 subjects). Formal limit-of-detection of studies are pending.

12 Phylogenetic analyses of sequences of SARS-CoV-2 viral RNA from high-coverage  
13 saliva samples of unique subjects (n=7) was done, and the lineages for all the samples tested  
14 were determined to be Clade O by GISAID nomenclature [19] and lineage B.6 by PANGOLIN  
15 system of nomenclature [20].

16

## 17 **Discussion**

18 Our study is concordant with multiple published works supporting saliva as an  
19 alternative sample for COVID-19 screening and diagnosis [7-15], and one of a minority  
20 where saliva was shown to be more sensitive than the corresponding NP swab [8,9,13],  
21 although the results by Leung and co-workers (53.7% saliva vs 47.4% NP swab, 95 subjects)  
22 were not statistically different [8].

23 Several reasons may account for this difference in these studies, including the strict  
24 collection of saliva that includes oropharyngeal secretions where the viral load is potentially

1 higher [8,9], or a higher volume of collection in the Yale study, where 1/3 of a urine cup  
2 (approximately 10 mls) had to be filled with saliva [13]. Because NP swabs were performed  
3 by trained healthcare staff locally, it is less likely that poor NP swab technique resulted in  
4 lower yield. The laboratory performing saliva testing similarly performed testing for all SN  
5 and most of the NP swabs for this study, and an extensive review including environmental  
6 testing revealed no evidence of laboratory contamination. Dithiothreitol (DTT) was used to  
7 pre-process all saliva samples here before RNA extraction, to resolve the commonly  
8 reported issue of saliva specimen viscosity, which can lead to false-negatives.

9           Interestingly but perhaps unsurprisingly, the use of different RT-PCR kits resulted in  
10 different test-positive rates in saliva in our study, suggesting that this can potentially be an  
11 important consideration for clinical laboratories, where more sensitive laboratory protocols  
12 should be deployed for clinical diagnosis as opposed to mass screening for low-prevalence  
13 populations. More validation will be required to confirm this.

14           SN swabs, however, appeared less sensitive compared to both NP swabs and saliva  
15 for the diagnosis of COVID-19. Although this was convenient, less time-consuming to  
16 perform relative to saliva collection and caused less discomfort compared to NP swabs, the  
17 markedly lower sensitivity should preclude its use where other sample types can be  
18 collected.

19           In our study, NGS can provide whole-genome profiling of -CoV-2 directly from clinical  
20 samples for phylogenic analysis. Formal limit-of-detection studies are still pending for the  
21 NGS workflow here; other groups have reported highly sensitive performance for NGS  
22 where a threshold of 5% genome coverage or 84 genome-equivalents per mL, was  
23 established as limit of detection [21]. The phylogeny results were consistent with the virus

1 belonging to viral type (Clade O, lineage B.6), known to be circulating in the geographical  
2 regions of Singapore and India.

3         There are several limitations to our work. Firstly, the study population was confined  
4 to young and middle-aged men who were either asymptomatic or had mild disease. The  
5 results cannot be extrapolated to other populations where there is a clear need for  
6 alternate sample types to NP swabs, such as in the paediatric population. Secondly, we did  
7 not extend the follow-up testing sufficiently to determine when saliva viral shedding  
8 stopped for the majority of subjects, although this has been explored in other studies [7,10].  
9 Thirdly, we did not test for the difference, if any, between naso-oropharyngeal saliva  
10 collection and saliva obtained from the mouth alone, although it is biologically plausible that  
11 the latter would result in lower sensitivity for COVID-19 diagnosis.

12         In conclusion, our study adds to the considerable body of evidence supporting saliva  
13 as a sensitive and less intrusive sample for COVID-19 diagnosis and further defines the role  
14 of oropharyngeal secretions and impact of different RT-PCR kits in increasing the sensitivity  
15 of testing. In our study, SN swabs were inferior as an alternate sample type to both NP  
16 swabs and saliva. Our study also provides evidence that a straightforward next-generation  
17 sequencing workflow can provide direct-from-sample phylogenetic analysis for public health  
18 decision-making.

19

## 20 **Acknowledgments**

21         We would like to thank S Siva Ranjini and Lenny Indrawati of Saw Swee Hock School  
22 of Public Health, the Singapore General Hospital, Woodlands Health Campus, and Singapore  
23 Armed Forces Medical Corp for supporting and facilitating the work at the purpose-built  
24 dormitory and CCF. We are also very grateful for the support and patience of the migrant

- 1 workers who participated in this study, and acknowledge the uncertainty and difficulties
- 2 they have experienced as a consequence of COVID-19.
- 3

1 **Tables**

2 **Table 1. Characteristics of recruited subjects**

Characteristic	Purpose-Built Dormitory ( <i>n</i> = 149)	CCF ( <i>n</i> = 51)
Male sex (%)	149 (100)	51 (100)
Median age (IQR), years	32 (28–37)	38 (36–41)
Symptomatic (%)	45 (30.2)	43 (84.3)
Number of subjects tested:		
Round 1	149	51
Round 2	40	51
Round 3	1	45
Number of symptomatic subjects with any positive test (%):		
Round 1	30/74 (40.5)	37/42 (88.1)
Round 2	15/32 (46.9)	37/41 (90.2)
Round 3	0 (0)	37/41 (90.2)
Number of asymptomatic subjects with any positive test (%):		
Round 1	44/74 (59.5)	5/42 (11.9)
Round 2	17/32 (53.1)	4/41 (9.8)
Round 3	1/1 (100)	4/41 (9.8)
Median (IQR) duration from symptom onset to test date, days – symptomatic subjects:		
Round 1	3 (2–4)	7 (6–8)
Round 2	5 (4–6)	10 (9–11)
Round 3	-	13 (12–14)
Median (IQR) duration from date of initial diagnosis <sup>a</sup> to test date, days – asymptomatic subjects:		
Round 1	0 (0–0)	5.5 (5–6)
Round 2	4 (3–6)	8.5 (8–9)
Round 3	11 (11)	11.5 (11–12)

3 CCF; community care facility, IQR; interquartile range

4 <sup>a</sup>For asymptomatic subjects recruited at the purpose-built dormitory, all three samples  
5 (nasopharyngeal, self-administered nasal, and saliva) were taken at the same time during  
6 round 1. For asymptomatic subjects recruited at CCF, subjects were diagnosed with COVID-  
7 19 via prior RT-PCR testing and only two samples (self-administered nasal and saliva) were  
8 taken during round 1.

9  
10  
11  
12  
13  
14  
15

1 **Table 2. Results of RT-PCR testing on samples**

	Tests on symptomatic individuals ( <i>n</i> = 188)	Tests on asymptomatic individuals ( <i>n</i> = 149)
Positive results, <i>n</i> (%):		
NP swab - CDC-LDT	123 (65.4)	27 (18.1)
SN swab - CDC-LDT	96 (51.1)	31 (20.8)
SN swab - Fortitude 2.1	98 (52.1)	21 (14.1)
Saliva – CDC-LDT	145 (77.1)	64 (43.0)
Saliva – Fortitude 2.1	123 (65.4)	44 (29.5)
Concordance of results among NP swabs (CDC-LDT), SN swabs (CDC-LDT), and saliva (CDC-LDT), <i>n</i> (%):		
NP swab only positive	6 (3.2)	1 (0.7)
Saliva only positive	24 (12.8)	35 (23.5)
SN swab only positive	2 (1.1)	8 (5.4)
NP swab and saliva positive	29 (15.4)	8 (5.4)
NP and SN swab positive	2 (1.1)	2 (1.3)
Saliva and SN swab positive	6 (3.2)	5 (3.4)
All three swabs positive in-tandem	86 (45.7)	16 (10.7)
Concordance of results among NP swabs (CDC-LDT), SN swabs (Fortitude 2.1), and saliva (CDC-LDT), <i>n</i> (%):		
NP swab only positive	5 (2.7)	1 (0.7)
Saliva only positive	25 (13.3)	39 (26.2)
SN swab only positive	1 (0.5)	4 (2.7)
NP swab and saliva positive	26 (13.8)	10 (6.7)
NP and SN swab positive	3 (1.6)	2 (1.3)
Saliva and SN swab positive	5 (2.7)	1 (0.7)
All three swabs positive in-tandem	89 (47.3)	14 (9.4)
Concordance of results among NP swabs (CDC-LDT), SN swabs (CDC-LDT), and saliva (Fortitude 2.1), <i>n</i> (%):		
NP swab only positive	12 (6.4)	4 (2.7)
Saliva only positive	14 (7.5)	20 (13.4)
SN swab only positive	4 (2.1)	9 (6.0)
NP swab and saliva positive	22 (11.7)	5 (3.4)
NP and SN swab positive	6 (3.2)	3 (2.0)
Saliva and SN swab positive	4 (2.1)	4 (2.7)
All three swabs positive in-tandem	82 (43.6)	15 (10.1)
Concordance of results among NP swabs (CDC-LDT), SN swabs (Fortitude 2.1), and saliva (Fortitude 2.1), <i>n</i> (%):		
NP swab only positive	9 (4.8)	5 (3.4)
Saliva only positive	14 (7.5)	23 (15.4)

SN swab only positive	2 (1.1)	4 (2.7)
NP swab and saliva positive	21 (11.2)	6 (4.0)
NP and SN swab positive	8 (4.3)	2 (1.3)
Saliva and SN swab positive	4 (2.1)	1 (0.7)
All three swabs positive in-tandem	84 (44.7)	14 (9.4)

1 NP; nasopharyngeal, SN; self-administered nasal, CDC-LDT; Centers for Disease Control and  
2 Prevention-Laboratory Developed Test  
3

4 **Table 3. Likelihood of test positivity over time in confirmed COVID-19 subjects**

Duration from onset of symptoms or initial diagnosis	NP Swab	SN Swab – CDC-LDT	SN Swab – Fortitude 2.1	Saliva – CDC-LDT	Saliva – Fortitude 2.1
0 – 7 days	74 (33.2%)	73 (32.7)	64 (28.7%)	122 (54.7%)	100 (44.8%)
8 – 14 days	73 (70.9%)	50 (48.5)	52 (50.5%)	79 (76.7%)	64 (62.1%)
≥ 15 days	3 (27.3%)	4 (36.4)	3 (27.3%)	8 (72.7%)	3 (27.3%)

5 NP; nasopharyngeal, SN; self-administered nasal, CDC-LDT; Centers for Disease Control and  
6 Prevention-Laboratory Developed Test  
7

8

9

10

11

12

13

14

15

16

17

18

19

1 **Figures**

2 **Figure 1. RT-PCR Ct values from onset of symptoms (symptomatic subjects) or time of**  
3 **diagnosis (asymptomatic subjects) for:**

4 A) NP swabs (tested via CDC-LDT) in symptomatic subjects

5 B) NP swabs (tested via CDC-LDT) in asymptomatic subjects

6 C) Self-administered nasal swabs (tested via CDC-LDT) for symptomatic subjects

7 D) Self-administered nasal swabs (tested via CDC-LDT) from asymptomatic subjects

8 E) Self-administered nasal swabs (tested via Fortitude 2.1) from symptomatic subjects

9 F) Self-administered nasal swabs (tested via Fortitude 2.1) from asymptomatic subjects

10 G) Saliva (tested via CDC-LDT) obtained from symptomatic subjects

11 H) Saliva (tested via CDC-LDT) obtained from asymptomatic subjects

12 I) Saliva (tested via Fortitude 2.1) obtained from symptomatic subjects

13 J) Saliva (tested via Fortitude 2.1) obtained from asymptomatic subjects

14

15

## 1   **References**


- 2       1. World Health Organization. Novel coronavirus (2019-nCoV) situation report – 1. 21st  
3       January 2020. Available at: [https://www.who.int/docs/default-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf)  
4       [source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf) Last  
5       accessed 2<sup>nd</sup> May 2020.
- 6       2. Worldometer. COVID-19 coronavirus outbreak. 15<sup>th</sup> July 2020. Available at:  
7       <https://www.worldometers.info/coronavirus/#countries> Last accessed 15<sup>th</sup> May  
8       2020.
- 9       3. Ministry of Health Singapore. COVID-19 Situation Report. Available at:  
10      <https://covid19sitrep.moh.gov.sg/> Last accessed 15<sup>th</sup> July 2020.
- 11     4. Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic features and clinical course of  
12     patients infected with SARS-CoV-2 in Singapore. JAMA. 2020. 3rd March 2020 [Epub  
13     ahead of print].
- 14     5. US Department of Health & Human Services (2020) Interim Guidelines for Collecting,  
15     Handling, and Testing Clinical Specimens from Persons Under Investigation (PUIs) for  
16     Coronavirus Disease 2019 (COVID-19). 29th April 2020. Available at:  
17     <https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html>  
18     Last accessed 15<sup>th</sup> July 2020.
- 19     6. Kwon KT, Ko JH, Shin H, et al. Drive-through screening center for COVID-19: a safe  
20     and efficient screening system against massive community outbreak. J Korean Med  
21     Sci. 2020;35:e123.
- 22     7. To KK, Tsang OT, Leung WS et al. Temporal profiles of viral load in posterior  
23     oropharyngeal saliva samples and serum antibody responses during infection by  
24     SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20:565-74.


- 1 8. Leung EC, Chow VC, Lee MK, Lai RW. Deep throat saliva as an alternative diagnostic  
2 specimen type for the detection of SARS-CoV-2. *J Med Virol*. 2020 4th July. doi:  
3 10.1002/jmv.26258. Online ahead of print.
- 4 9. Cheuk S, Wong Y, Tse H, Siu HK, Kwong TS, Chu MY, et al. Posterior oropharyngeal  
5 saliva for the detection of SARS-CoV-2. *Clin Infect Dis*. 2020 [In press].
- 6 10. Zheng S, Fan Y Yu F, et al. Viral load dynamics and disease severity in patients  
7 infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020:  
8 retrospective cohort study. *BMJ*. 2020;369:m1443.
- 9 11. Azzi L, Carcano G, Gianfagna F, et al. Saliva is a reliable tool to detect SARS-CoV-2. *J*  
10 *Infect*. 2020. 14<sup>th</sup> April 2020 [Epub ahead of print]
- 11 12. Williams E, Bond K, Zhang B, et al. Saliva as a non-invasive specimen for detection of  
12 SARS-CoV-2. *J Clin Microbiol*. 2020. 21<sup>st</sup> April 2020 [Epub ahead of print]
- 13 13. Wylie AL, Fournier J, Casanovas-Massana A, et al. Saliva is more sensitive for SARS-  
14 CoV-2 detection in COVID-19 patients than nasopharyngeal swabs. *MedRxiv*. 2020.  
15 Available at:  
16 [https://www.medrxiv.org/content/10.1101/2020.04.16.20067835v1#disqus\\_thread](https://www.medrxiv.org/content/10.1101/2020.04.16.20067835v1#disqus_thread)  
17 Last accessed 2<sup>nd</sup> May 2020.
- 18 14. Jamal AJ, Mozafarihashjin M, Coomes E, Powis J, Li AX, Paterson A, Anceva-Sami S,  
19 Barati S, Crowl G, Faheem A, Farooqi L, Khan S, Prost K, Poutanen S, Taylor M, Yip L,  
20 Zhong XZ, McGeer AJ, Mubareka S; Toronto Invasive Bacterial Diseases Network  
21 COVID-19 Investigators. Sensitivity of nasopharyngeal swabs and saliva for the  
22 detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). *Clin*  
23 *Infect Dis*. 2020 Jun 25:ciaa848. doi: 10.1093/cid/ciaa848. Online ahead of print.


- 1 15. Nagura-Ikeda M, Imai K, Tabata S, Miyoshi K, Murahara N, Mizuno T, et al. Clinical  
2 evaluation of self-collected saliva by RT-qPCR, direct RT-qPCR, RT-LAMP, and a rapid  
3 antigen test to diagnose COVID-19. J Clin Microbiol. 2020 [In press].
- 4 16. Czumbel LM, Kiss S, Farkas N, Mandel I, Hegyi AE, Nagy, AK, et al. Saliva as a  
5 Candidate for COVID-19 Diagnostic Testing: A Meta-Analysis. MedRxiv. 2020.  
6 Available at: <https://www.medrxiv.org/content/10.1101/2020.05.26.20112565v1>
- 7 17. Centers for Disease Control and Prevention. Research Use Only 2019-Novel  
8 Coronavirus (2019-nCoV) Real-time RT-PCR Primers and Probes. Available at:  
9 <https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html>  
10 Last accessed 15th July 2020.
- 11 18. The Statutes of the Republic of Singapore. Infectious Diseases Act (Chapter 137).  
12 National Public Health Research. Available at:  
13 <https://sso.agc.gov.sg/Act/IDA1976#P1VIIA-> Last accessed 15<sup>th</sup> July 2020.
- 14 19. Han AX, Parker E, Scholer F, Maurer-Stroh S, Russell CA. Phylogenetic Clustering by  
15 Linear Integer Programming (PhyCLIP). Mol Biol Evol. 2019;36: 1580–1595.  
16 <https://doi.org/10.1093/molbev/msz053>
- 17 20. Rambaut, A., Holmes, E.C., O’Toole, Á. et al. A dynamic nomenclature proposal for  
18 SARS-CoV-2 lineages to assist genomic epidemiology. Nat Microbiol. 2020.  
19 <https://doi.org/10.1038/s41564-020-0770-5>
- 20 21. Hilaire BGS, Durand NC, Mitra N, Pulido SG, Mahajan R, Blackburn A, et al. A rapid,  
21 low cost, and highly sensitive SARS-CoV-2 diagnostic based on whole genome  
22 sequencing. bioRxiv. 2020. <https://doi:10.1101/2020.04.25.061499>


23

24










C<sub>19</sub>Au in nasal swabs



95% CI



Fitted values

